

 SENDERRA Specialty Pharmacy 1301 E. Arapaho Rd., Ste. 101 Richardson, TX 75081 <i>This prescription form is to be sent and received via fax</i>	Juvenile Idiopathic Arthritis (JIA) Enrollment Form Physician Offices Call: 855-460-7928 Fax: 888-777-5645	Prescriber: _____ Supervising Physician: _____ Address: _____ Phone: _____ Fax: _____ Contact: _____	NPI: _____ NPI: _____ Tax ID: _____
--	---	--	--

PATIENT INFORMATION					
Name: _____	<input type="checkbox"/> M <input type="checkbox"/> F	DOB: ____/____/____	SS#: _____		
Street: _____	City: _____	State: _____	ZIP: _____		
Phone: _____	Alt. Phone: _____	<input type="checkbox"/> English <input type="checkbox"/> Spanish <input type="checkbox"/> Other: _____	Wt.: _____	Ht.: _____	

<input type="checkbox"/> New <input type="checkbox"/> Refill	Ship by: ____/____/____	SHIP TO: <input type="checkbox"/> Patient's Home <input type="checkbox"/> Doctor's Office <input type="checkbox"/> Other: _____
--	-------------------------	---

Drug	Directions	Quantity	Refills
Actemra® <input type="checkbox"/> Vials <input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> ACTPen™	INTRAVENOUS (IV): <input type="checkbox"/> P JIA – Infuse 10 mg/kg every 4 weeks via IV (< 30 kg) <input type="checkbox"/> P JIA – Infuse 8 mg/kg every 4 weeks via IV (≥ 30 kg) ***WEIGHT REQUIRED*** _____ <input type="checkbox"/> S JIA – Infuse 12 mg/kg every 2 weeks via IV (< 30 kg) <input type="checkbox"/> S JIA – Infuse 8 mg/kg every 2 weeks via IV (≥ 30 kg)		
	SUBCUTANEOUS (SQ): <input type="checkbox"/> P JIA – Inject 162 mg SQ once every 3 weeks (< 30 kg) <input type="checkbox"/> P JIA – Inject 162 mg SQ once every 2 weeks (≥ 30 kg) ***WEIGHT REQUIRED*** _____ <input type="checkbox"/> S JIA – Inject 162 mg SQ once every 2 weeks (< 30 kg) <input type="checkbox"/> S JIA – Inject 162 mg SQ once weekly (≥ 30 kg)	1 2 2 4	
Enbrel® <input type="checkbox"/> SureClick® Pen <input type="checkbox"/> Mini™ with AutoTouch™ <input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> 25 mg <input type="checkbox"/> 50 mg <input type="checkbox"/> Vials 25 mg	<input type="checkbox"/> Inject ____ mg (0.8mg/kg x ____kg SQ every week) (≤63 kg) ***WEIGHT REQUIRED*** _____ <input type="checkbox"/> Inject 50 mg SQ every week (>63 kg)	____ x 25 mg/mL 4	
HP Acthar® Gel <input type="checkbox"/> 5mL multidose vial	Dose: _____ <input type="checkbox"/> Units <input type="checkbox"/> mL Route of Administration: <input type="checkbox"/> IM <input type="checkbox"/> SQ	Schedule/Frequency: _____ _____	Quantity of Vials: _____
Humira® Citrate Free <input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> Pen	<input type="checkbox"/> Inject 10 mg SQ every other week (10 kg to <15 kg) <input type="checkbox"/> Inject 20 mg SQ every other week (15 kg to <30 kg) ***WEIGHT REQUIRED*** _____ <input type="checkbox"/> Inject 40 mg SQ every other week (≥ 30 kg)		
Humira® <input type="checkbox"/> Vials <input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> Pen	<input type="checkbox"/> Inject 10 mg SQ every other week (10 kg to <15 kg) <input type="checkbox"/> Inject 20 mg SQ every other week (15 kg to <30 kg) ***WEIGHT REQUIRED*** _____ <input type="checkbox"/> Inject 40 mg SQ every other week (≥ 30 kg)		
Orencia® <input type="checkbox"/> Vials WEIGHT REQUIRED: _____ <input type="checkbox"/> Pre-filled Syringe <input type="checkbox"/> ClickJect™	INTRAVENOUS (IV): <input type="checkbox"/> INITIAL: Infuse _____ mg via IV on week 0, 2, and 4 <input type="checkbox"/> MAINTENANCE: Infuse _____ mg via IV every 4 weeks SUBCUTANEOUS (SQ): <input type="checkbox"/> Inject 50 mg SQ once weekly (10 kg to less than 25 kg) <input type="checkbox"/> Inject 87.5 mg SQ once weekly (25 kg to less than 50 kg) ***WEIGHT REQUIRED*** _____ <input type="checkbox"/> Inject 125 mg SQ once weekly (≥50 kg)	QS 3 doses QS: 1 dose 4	

MEDICAL INFORMATION

*****PLEASE FAX COPY OF PRESCRIPTION/MEDICAL CARD, FRONT AND BACK, AS WELL AS ANY CLINICAL NOTES REGARDING THERAPY*****

PREVIOUS THERAPIES:	Tried & Failed (Duration):	Not Tolerated:	Contraindication:
<input type="checkbox"/> Methotrexate	<input type="checkbox"/> (____)	<input type="checkbox"/>	_____
<input type="checkbox"/> Sulfasalazine	<input type="checkbox"/> (____)	<input type="checkbox"/>	_____
<input type="checkbox"/> Meloxicam	<input type="checkbox"/> (____)	<input type="checkbox"/>	_____
<input type="checkbox"/> Naproxen/Aleve	<input type="checkbox"/> (____)	<input type="checkbox"/>	_____
<input type="checkbox"/> Enbrel	<input type="checkbox"/> (____)	<input type="checkbox"/>	_____
<input type="checkbox"/> Humira	<input type="checkbox"/> (____)	<input type="checkbox"/>	_____
<input type="checkbox"/> _____	<input type="checkbox"/> (____)	<input type="checkbox"/>	_____

Date of Diagnosis: ____/____/____ **Allergies:** _____
 M08.00 Unspecified Juvenile Idiopathic Arthritis of Unspecified Site Other: _____
Active TB is ruled out: Yes No **Date:** ____/____/____ **Hep B ruled out/treated:** Yes No **Date:** ____/____/____

Additional Clinical Information: _____

INJECTION TRAINING

Patient has received pen and injection training
 Physician's office to provide injection training
 Senderra to coordinate injection training

PRESCRIBER SIGNATURE

To Prescriber: By signing this form and utilizing our services, you are also authorizing Senderra Rx to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies, and co-pay assistance foundations.

Prescriber: _____	Date: ____/____/____
--------------------------	-----------------------------

CONFIDENTIALITY NOTICE

IMPORTANT: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute, or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.